Werewolf Therapeutics (HOWL) Non-Current Deffered Revenue (2022 - 2024)

Werewolf Therapeutics has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $431000.0 in Q1 2024.

• Non-Current Deffered Revenue for Q1 2024 came in at $431000.0, down 64.08% year-over-year; the trailing twelve-month figure through Mar 2024 was $431000.0 (down 64.08% YoY), and the FY2023 annual result was $433000.0, down 61.61% from the prior year.
• Non-Current Deffered Revenue held at $431000.0 in Q1 2024, from $433000.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $1.3 million in Q2 2022 and troughed at $343000.0 in Q3 2022.
• A 3-year average of $779375.0 and a median of $700000.0 in 2023 frame the typical range for Non-Current Deffered Revenue.
• The widest annual swing landed in 2023, when Non-Current Deffered Revenue soared 74.93%; it then tumbled 64.08% in 2024.
• A 3-year view of Non-Current Deffered Revenue shows it stood at $1.1 million in 2022, then tumbled by 61.61% to $433000.0 in 2023, then fell by 0.46% to $431000.0 in 2024.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $431000.0 in Q1 2024, $433000.0 in Q4 2023, and $600000.0 in Q3 2023.